Sorin Group Launches a New Complete Portfolio of Pacing, Defibrillation and Left Ventricular Leads

SORIN GROUP

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announces CE Mark approval and commercial launch for a comprehensive new range of pacing, defibrillation and left ventricular leads. Designed for safety and long term reliability, TILDA pacing leads, VIGILA defibrillation leads and CELERITY left ventricular lead families offer multiple implant options to accommodate patients’ needs and physicians’ preferences. TILDA, VIGILA and CELERITY leads’ lasting performance and quality, combined with Sorin Group’s unique algorithms, provide reliable and individualized therapies for patients. Learn more at http://bit.ly/yDVObp